<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285414</url>
  </required_header>
  <id_info>
    <org_study_id>MPC-6827-021</org_study_id>
    <nct_id>NCT01285414</nct_id>
  </id_info>
  <brief_title>Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase 2 Study of Verubulin With Radiation Therapy and Temozolomide in Subjects Newly Diagnosed With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myrexis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myrexis Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This, international, multi-center, Phase 2 study of verubulin will be conducted in patients
      with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts.
      Part A is an open-label dose finding study that will determine the safety and tolerability of
      verubulin in combination with standard treatment. Part B is a randomized open-label study
      that will investigate progression-free survival and overall survival of patients receiving
      verubulin, at the dose determined in Part A, in combination with standard treatment versus
      standard treatment alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Safety</measure>
    <time_frame>14 weeks</time_frame>
    <description>Assess the number and percentage of subjects with adverse events, abnormal laboratory parameters, and ECG changes as measures of safety and tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: 9 Mo Progression-free survival</measure>
    <time_frame>9 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetic Parameters</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measure the amount of verubulin in the body at specific time points when given with standard of care Radiation Therapy and Temozolomide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: 6 Mo Progression Free Survival</measure>
    <time_frame>6 month</time_frame>
    <description>Assess 6-month progression-free survival and compare median progression-free survival time for Radiation Therapy plus Temozolomide (TMZ)plus verubulin to standard of care (Radiation Therapy plus TMZ alone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>18 months</time_frame>
    <description>Assess overall survival and compare median overall survival time for Radiation Therapy plus Temozolomide (TMZ)plus verubulin to standard of care (Radiation Therapy plus TMZ alone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: 12 Mo Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Assess 12-month progression-free survival and compare median progression-free survival time for Radiation Therapy plus Temozolomide (TMZ)plus verubulin to standard of care (Radiation Therapy plus TMZ alone)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Verubulin &amp; standard of care (RT &amp; TMZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care (RT &amp; TMZ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care Radiation Therapy and Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verubulin</intervention_name>
    <description>Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide &amp; Radiation Therapy</description>
    <arm_group_label>Verubulin &amp; standard of care (RT &amp; TMZ)</arm_group_label>
    <other_name>Azixa</other_name>
    <other_name>MPC-6827</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide &amp; Radiation Therapy</intervention_name>
    <description>Temozolomide &amp; Radiation Therapy</description>
    <arm_group_label>Standard of care (RT &amp; TMZ)</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have histologically proven, newly diagnosed glioblastoma multiforme

          2. Age ≥ 18 years and &lt; 70 years

          3. Have an ECOG performance score of 0, 1, or 2, or KPS ≥ 70

          4. Have adequate bone marrow function , liver function, and kidney function before
             starting therapy

          5. Begin study therapy no more than 6 weeks after surgery or biopsy

          6. Subjects that have had surgery must have an MRI ≤ 72 hours after surgery

        Exclusion Criteria:

          1. Have a carmustine implant (e.g., Gliadel® Wafer)

          2. Have uncontrolled hypertension (SBP &gt; 140 mmHg or DBP &gt; 90 mmHg for more than 1 week)

          3. Have a left ventricular ejection fraction below the lower limit of the reference range
             for the institution, as measured by multiple gated acquisition (MUGA) or
             echocardiogram (ECHO)

          4. Have Troponin-I or Troponin T at Screening visit elevated above the upper limit of the
             reference range of the local institution

          5. Have an increasing steroid requirement, indicative of a rapidly progressive disease

          6. Have evidence of new, active intra tumor hemorrhage ≥ CTCAE Grade 2

          7. Have had prior cranial radiotherapy

          8. Have history of stroke and/or transient ischemic attack within 2 years of screening

          9. Have history of cardiovascular disease (e.g., angina, myocardial infarction,
             congestive heart failure, etc.) within 2 years of screening

         10. Be pregnant or breast feeding

         11. Have a history of hypersensitivity reaction to Cremophor® EL

         12. Have a history of hypersensitivity reaction or intolerance to temozolomide or
             dacarbazine (DTIC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Beelen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Myrexis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.myrexis.com</url>
    <description>Additional Information</description>
  </link>
  <reference>
    <citation>Sirisoma N, Pervin A, Zhang H, Jiang S, Willardsen JA, Anderson MB, Mather G, Pleiman CM, Kasibhatla S, Tseng B, Drewe J, Cai SX. Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J Med Chem. 2009 Apr 23;52(8):2341-51. doi: 10.1021/jm801315b.</citation>
    <PMID>19296653</PMID>
  </reference>
  <reference>
    <citation>Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71.</citation>
    <PMID>17575155</PMID>
  </reference>
  <reference>
    <citation>Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther. 2010 Dec;9(12):3410-9. doi: 10.1158/1535-7163.MCT-10-0516.</citation>
    <PMID>21159616</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Brain Neoplasms</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Verubulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

